US-based medical technology company GE HealthCare has teamed up with medical software provider Medis Medical Imaging to advance precision care in coronary artery disease (CAD).

Under the collaboration, the two companies will work together for the further development and commercialisation of Medis’ Quantitative Flow Ratio (Medis QFR).

Medis QFR is a non-invasive approach to the assessment of coronary physiology.

GE HealthCare will offer Medis QFR as part of its interventional cardiology portfolio, which is built around the Allia patient management Platform.

GE HealthCare global intervention general manager Arnaud Marie said: “We continue to see an evolution in how clinicians work to treat cardiovascular disease and want to give clinicians the tools, along with the flexibility and adaptability, they need to enable better outcomes for their patients.

“In the assessment of coronary artery disease, QFR represents a significant advancement in how efficiently it can provide critical insights.

“We’re excited to collaborate with Medis Medical Imaging to add innovative, non-invasive, image-based QFR to our portfolio of offerings around our Allia IGS platform to streamline the experience for clinicians and help us to deliver on our vision for the future image-guided therapy.”

CAD is a type of heart disease that develops when the coronary arteries narrow down, and the heart cannot deliver the required volume of oxygen-rich blood to the heart.

The disease can be accurately diagnosed through invasive coronary angiography, which helps clinicians determine whether a patient needs treatment, and identify which lesion to treat.

GE HealthCare is collaborating with Medis Medical Imaging to bring Medis QFR, which advances precision care in interventional cardiology.

Clinicians can now use Medis QFR as an emerging, non-invasive, image-based diagnostic approach to the assessment of coronary artery physiology and the treatment of CAD.

In a recent study, QFR guidance improved lesion selection for PCI, including the reduction in myocardial infraction and ischemia-driven revascularisation.

GE HealthCare said that technologies like Medis QFR enhance its portfolio of interventional cardiology solutions built around the Allia Platform.

Medis Medical Imaging CEO Maya Barley said: “We are absolutely delighted to be taking this next step with GE HealthCare, a fellow leader in the interventional cardiology domain.

“Building on Medis QFR’s decade of AI research, customer-focused product development, clinical evidence generation and business development, we are excited to be able to further accelerate our efforts around Medis QFR to enable more hospitals and clinicians to apply physiology in day-to-day interventional practice.”